124 related articles for article (PubMed ID: 15349718)
1. Molecular and clinical response to angiotensin II receptor antagonist in kidney transplant patients with chronic allograft nephropathy.
Mas VR; Alvarellos T; Maluf DG; Ferreira-Gonzalez A; Oliveros L; Maldonado RA; de Boccardo G
Transpl Int; 2004 Oct; 17(9):540-4. PubMed ID: 15349718
[TBL] [Abstract][Full Text] [Related]
2. Renal effects of long-term leptin infusion and preventive role of losartan treatment in rats.
Gunduz Z; Dursun N; Akgun H; Ozturk F; Okur H; Koc N
Regul Pept; 2005 Dec; 132(1-3):59-66. PubMed ID: 16229907
[TBL] [Abstract][Full Text] [Related]
3. Urinary TGF-beta1 as an indicator of antiproteinuric response to angiotensin II receptor blocker in proteinuric renal diseases.
Park HC; Choi HY; Kim BS; An HR; Lee JS; Ha SK; Han DS
Biomed Pharmacother; 2009 Nov; 63(9):672-8. PubMed ID: 19278811
[TBL] [Abstract][Full Text] [Related]
4. [Role of transforming growth factor beta-1 gene polymorphisms in the development of chronic allograft nephropathy in renal transplant recipients].
Iñigo P; Lario S; Campistol JM; Bescós M; Campos B; Oppenheimer F
Nefrologia; 2003; 23(4):312-20. PubMed ID: 14558330
[TBL] [Abstract][Full Text] [Related]
5. Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy.
Campistol JM; Iñigo P; Jimenez W; Lario S; Clesca PH; Oppenheimer F; Rivera F
Kidney Int; 1999 Aug; 56(2):714-9. PubMed ID: 10432413
[TBL] [Abstract][Full Text] [Related]
6. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
Renke M; Tylicki L; Rutkowski P; Wojnarowski K; Lysiak-Szydlowska W; Rutkowski B
Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729
[TBL] [Abstract][Full Text] [Related]
7. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
[TBL] [Abstract][Full Text] [Related]
8. The effect of different immunosuppressive regimens on TGF-beta1 expression in kidney transplant patients.
Matl I; Viklický O; Voska L; Lodererová A; Vítko S
Transpl Int; 2005 Jun; 18(6):668-71. PubMed ID: 15910291
[TBL] [Abstract][Full Text] [Related]
9. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
10. Effect of losartan on slowing progression of chronic allograft nephropathy.
Wang PX; Fan MQ; Huang CB; Feng JY; Xiao Y; Fang ZQ; Zhang YP
Chin Med Sci J; 2005 Dec; 20(4):231-6. PubMed ID: 16422249
[TBL] [Abstract][Full Text] [Related]
11. TGF-beta1 in chronic allograft nephropathy following renal transplantation.
Harris S; Coupes BM; Roberts SA; Roberts IS; Short CD; Brenchley PE
J Nephrol; 2007; 20(2):177-85. PubMed ID: 17514622
[TBL] [Abstract][Full Text] [Related]
12. Endothelin-mediated oncofetal fibronectin expression in chronic allograft nephropathy.
Siddiqui I; Khan ZA; Lian D; Jiang J; Zhong R; Garcia B; Chakrabarti S
Transplantation; 2006 Aug; 82(3):406-14. PubMed ID: 16906041
[TBL] [Abstract][Full Text] [Related]
13. Prediction of chronic renal allograft dysfunction from evaluations of TGFBeta1 and the renin-angiotensin system.
Yamada K; Hatakeyama E; Arita S; Sakamoto K; Kashiwabara H; Hamaguchi K
Clin Exp Nephrol; 2003 Sep; 7(3):238-42. PubMed ID: 14586721
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
Zhu S; Liu Y; Wang L; Meng QH
Nephrol Dial Transplant; 2008 Sep; 23(9):2841-6. PubMed ID: 18390891
[TBL] [Abstract][Full Text] [Related]
15. Effects of angiotensin II receptor blocker on proteinuria in renal transplant recipients.
Tanji N; Ohoka H; Shimamoto K; Ikeda T; Miyauchi Y; Yokoyama M
In Vivo; 2004; 18(4):433-6. PubMed ID: 15369180
[TBL] [Abstract][Full Text] [Related]
16. Urinary kallikrein excretion is related to renal function change and inflammatory status in chronic kidney disease patients receiving angiotensin II receptor blocker treatment.
Chiang WC; Lin SL; Chen YM; Wu KD; Tsai TJ
Nephrology (Carlton); 2008 Jun; 13(3):198-203. PubMed ID: 18315702
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacogenetics of angiotensin system in non diabetic nephropathy].
Coto E; Marín R; Alvarez V; Praga M; Fernández Andrade C; Arias M; Poveda R; Vallés M; Galcerán JM; Luño J; Rivera F; Campistol JM
Nefrologia; 2005; 25(4):381-6. PubMed ID: 16231503
[TBL] [Abstract][Full Text] [Related]
18. [TGF-beta1 in allograft and long-term renal function].
Wang PX; Huang XY; Wang AJ; Huang CB; Fan MQ; Zhang YP
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Dec; 29(6):700-3. PubMed ID: 16114562
[TBL] [Abstract][Full Text] [Related]
19. TNF-alpha and TGF-beta1 gene polymorphisms and renal allograft rejection in Koreans.
Park JY; Park MH; Park H; Ha J; Kim SJ; Ahn C
Tissue Antigens; 2004 Dec; 64(6):660-6. PubMed ID: 15546338
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor-beta in human diabetic nephropathy: effects of ACE inhibition.
Langham RG; Kelly DJ; Gow RM; Zhang Y; Cordonnier DJ; Pinel N; Zaoui P; Gilbert RE
Diabetes Care; 2006 Dec; 29(12):2670-5. PubMed ID: 17130203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
